

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

---

**SECTION 1. IDENTIFICATION**

Product name : Sitagliptin / Simvastatin Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 855 Leandro N. Alem St., 8 Floor  
Buenos Aires, Argentina C1001AFB

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Skin corrosion/irritation : Category 3

Serious eye damage/eye irritation : Category 2A

Skin sensitization : Category 1

Specific target organ toxicity - repeated exposure : Category 2 (Liver, muscle, optic nerve, Eye)

Short-term (acute) aquatic hazard : Category 3

Long-term (chronic) aquatic hazard : Category 3

**GHS label elements**

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H316 Causes mild skin irritation.

## Sitagliptin / Simvastatin Formulation

Version 8.1      Revision Date: 11.08.2025      SDS Number: 24478-00025      Date of last issue: 06.07.2024  
Date of first issue: 21.10.2014

H317 May cause an allergic skin reaction.  
H319 Causes serious eye irritation.  
H373 May cause damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.  
H412 Harmful to aquatic life with long lasting effects.

## Precautionary Statements

:

**Prevention:**

P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ eye protection/ face protection.

**Response:**

P302 + P352 IF ON SKIN: Wash with plenty of water.  
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P314 Get medical advice/ attention if you feel unwell.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
P337 + P313 If eye irritation persists: Get medical advice/ attention.  
P362 + P364 Take off contaminated clothing and wash it before reuse.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

| Chemical name         | CAS-No.     | Concentration (% w/w) |
|-----------------------|-------------|-----------------------|
| Sitagliptin Phosphate | 654671-77-9 | >= 10 -< 20           |
| Cellulose             | 9004-34-6   | >= 5 -< 10            |
| Simvastatin           | 79902-63-9  | >= 2,5 -< 5           |
| Starch                | 9005-25-8   | >= 1 -< 5             |
| Ascorbic acid         | 50-81-7     | >= 1 -< 5             |
| Titanium dioxide      | 13463-67-7  | >= 0,1 -< 1           |

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

## Sitagliptin / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

|                                                             |   |                                                                                                                                                                                                              |
|-------------------------------------------------------------|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| If inhaled                                                  | : | If inhaled, remove to fresh air.<br>Get medical attention.                                                                                                                                                   |
| In case of skin contact                                     | : | In case of contact, immediately flush skin with plenty of water.<br>Remove contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse. |
| In case of eye contact                                      | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.<br>If easy to do, remove contact lens, if worn.<br>Get medical attention.                                           |
| If swallowed                                                | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention if symptoms occur.<br>Rinse mouth thoroughly with water.                                                                                      |
| Most important symptoms and effects, both acute and delayed | : | Causes mild skin irritation.<br>May cause an allergic skin reaction.<br>Causes serious eye irritation.<br>May cause damage to organs through prolonged or repeated exposure.                                 |
| Protection of first-aiders                                  | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).                                  |
| Notes to physician                                          | : | Treat symptomatically and supportively.                                                                                                                                                                      |

**SECTION 5. FIRE-FIGHTING MEASURES**

|                                                |   |                                                                                                                                                                                                                                                 |
|------------------------------------------------|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Suitable extinguishing media                   | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical                                                                                                                                                      |
| Unsuitable extinguishing media                 | : | None known.                                                                                                                                                                                                                                     |
| Specific hazards during fire fighting          | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.<br>Exposure to combustion products may be a hazard to health.                   |
| Hazardous combustion products                  | : | Carbon oxides<br>Metal oxides<br>Oxides of phosphorus                                                                                                                                                                                           |
| Specific extinguishing methods                 | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do so.<br>Evacuate area. |
| Special protective equipment for fire-fighters | : | In the event of fire, wear self-contained breathing apparatus.<br>Use personal protective equipment.                                                                                                                                            |

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

- 
- |                                                                     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------------------------------------------------------------|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Personal precautions, protective equipment and emergency procedures | : | Use personal protective equipment.<br>Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Environmental precautions                                           | : | Avoid release to the environment.<br>Prevent further leakage or spillage if safe to do so.<br>Retain and dispose of contaminated wash water.<br>Local authorities should be advised if significant spillages cannot be contained.                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Methods and materials for containment and cleaning up               | : | Sweep up or vacuum up spillage and collect in suitable container for disposal.<br>Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).<br>Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.<br>Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.<br>Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

---

**SECTION 7. HANDLING AND STORAGE**

- |                             |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------------------|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Technical measures          | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Local/Total ventilation     | : | Use only with adequate ventilation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Advice on safe handling     | : | Do not get on skin or clothing.<br>Do not breathe dust.<br>Do not swallow.<br>Do not get in eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Conditions for safe storage | : | Keep in properly labeled containers.<br>Store in accordance with the particular national regulations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Materials to avoid          | : | Do not store with the following product types:<br>Strong oxidizing agents<br>Self-reactive substances and mixtures<br>Organic peroxides<br>Explosives                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## Sitagliptin / Simvastatin Formulation

Version 8.1      Revision Date: 11.08.2025      SDS Number: 24478-00025      Date of last issue: 06.07.2024  
 Date of first issue: 21.10.2014

## Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

| Components            | CAS-No.                                                          | Value type<br>(Form of exposure) | Control parameters / Permissible concentration | Basis    |
|-----------------------|------------------------------------------------------------------|----------------------------------|------------------------------------------------|----------|
| Sitagliptin Phosphate | 654671-77-9                                                      | TWA                              | 0.6 mg/m <sup>3</sup> (OEB 2)                  | Internal |
| Cellulose             | 9004-34-6                                                        | CMP                              | 10 mg/m <sup>3</sup>                           | AR OEL   |
|                       |                                                                  | TWA                              | 10 mg/m <sup>3</sup>                           | ACGIH    |
| Simvastatin           | 79902-63-9                                                       | TWA                              | 25 µg/m <sup>3</sup> (OEB 3)                   | Internal |
|                       | Further information: DSEN                                        |                                  |                                                |          |
|                       |                                                                  | Wipe limit                       | 250 µg/100 cm <sup>2</sup>                     | Internal |
| Starch                | 9005-25-8                                                        | CMP                              | 10 mg/m <sup>3</sup>                           | AR OEL   |
|                       | Further information: A4 - Not classifiable as a human carcinogen |                                  |                                                |          |
|                       |                                                                  | TWA                              | 10 mg/m <sup>3</sup>                           | ACGIH    |
| Ascorbic acid         | 50-81-7                                                          | TWA                              | 5000 µg/m <sup>3</sup> (OEB 1)                 | Internal |
| Titanium dioxide      | 13463-67-7                                                       | CMP                              | 10 mg/m <sup>3</sup>                           | AR OEL   |
|                       | Further information: A4 - Not classifiable as a human carcinogen |                                  |                                                |          |

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

## Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

Hygiene measures : Use appropriate degowning techniques to remove potentially contaminated clothing.  
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Contaminated work clothing should not be allowed out of the workplace.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

|                                                  |                                                                                   |
|--------------------------------------------------|-----------------------------------------------------------------------------------|
| Appearance                                       | : powder                                                                          |
| Color                                            | : pink                                                                            |
| Odor                                             | : No data available                                                               |
| Odor Threshold                                   | : No data available                                                               |
| pH                                               | : No data available                                                               |
| Melting point/freezing point                     | : No data available                                                               |
| Initial boiling point and boiling range          | : No data available                                                               |
| Flash point                                      | : Not applicable                                                                  |
| Evaporation rate                                 | : Not applicable                                                                  |
| Flammability (solid, gas)                        | : May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids)                           | : No data available                                                               |
| Upper explosion limit / Upper flammability limit | : No data available                                                               |
| Lower explosion limit / Lower flammability limit | : No data available                                                               |
| Vapor pressure                                   | : Not applicable                                                                  |
| Relative vapor density                           | : Not applicable                                                                  |
| Relative density                                 | : No data available                                                               |
| Density                                          | : No data available                                                               |

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

|                                        |                                                            |
|----------------------------------------|------------------------------------------------------------|
| Solubility(ies)                        |                                                            |
| Water solubility                       | : No data available                                        |
| Partition coefficient: n-octanol/water | : Not applicable                                           |
| Autoignition temperature               | : No data available                                        |
| Decomposition temperature              | : No data available                                        |
| Viscosity                              |                                                            |
| Viscosity, kinematic                   | : Not applicable                                           |
| Explosive properties                   | : Not explosive                                            |
| Oxidizing properties                   | : The substance or mixture is not classified as oxidizing. |
| Molecular weight                       | : No data available                                        |
| Particle characteristics               |                                                            |
| Particle size                          | : No data available                                        |

**SECTION 10. STABILITY AND REACTIVITY**

|                                    |                                                                                                                              |
|------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Reactivity                         | : Not classified as a reactivity hazard.                                                                                     |
| Chemical stability                 | : Stable under normal conditions.                                                                                            |
| Possibility of hazardous reactions | : May form explosive dust-air mixture during processing, handling or other means.<br>Can react with strong oxidizing agents. |
| Conditions to avoid                | : Heat, flames and sparks.<br>Avoid dust formation.                                                                          |
| Incompatible materials             | : Oxidizing agents                                                                                                           |
| Hazardous decomposition products   | : No hazardous decomposition products are known.                                                                             |

**SECTION 11. TOXICOLOGICAL INFORMATION**

|                                          |                                                          |
|------------------------------------------|----------------------------------------------------------|
| Information on likely routes of exposure | : Inhalation<br>Skin contact<br>Ingestion<br>Eye contact |
|------------------------------------------|----------------------------------------------------------|

**Acute toxicity**

Not classified based on available information.

**Components:****Sitagliptin Phosphate:**

|                     |                                                          |
|---------------------|----------------------------------------------------------|
| Acute oral toxicity | : LD50 (Rat): > 3.000 mg/kg<br>LD50 (Mouse): 3.000 mg/kg |
|---------------------|----------------------------------------------------------|

**Cellulose:**

## Sitagliptin / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

**Simvastatin:**

Acute oral toxicity : LD50 (Rat): 5.000 mg/kg  
LD50 (Mouse): 3.800 mg/kg

**Starch:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg  
Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

**Ascorbic acid:**

Acute oral toxicity : LD50 (Rat): 11.900 mg/kg

**Titanium dioxide:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 6,82 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity

**Skin corrosion/irritation**

Causes mild skin irritation.

**Components:****Sitagliptin Phosphate:**

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

**Simvastatin:**

Species : Rabbit  
Remarks : Moderate skin irritation

**Ascorbic acid:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Titanium dioxide:**

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

---

|         |   |                    |
|---------|---|--------------------|
| Species | : | Rabbit             |
| Result  | : | No skin irritation |

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****Sitagliptin Phosphate:**

|         |   |                     |
|---------|---|---------------------|
| Species | : | Rabbit              |
| Result  | : | Irritating to eyes. |
| Method  | : | Draize Test         |

**Simvastatin:**

|         |   |                   |
|---------|---|-------------------|
| Species | : | Rabbit            |
| Remarks | : | slight irritation |

**Starch:**

|         |   |                   |
|---------|---|-------------------|
| Species | : | Rabbit            |
| Result  | : | No eye irritation |

**Ascorbic acid:**

|         |   |                         |
|---------|---|-------------------------|
| Species | : | Rabbit                  |
| Result  | : | No eye irritation       |
| Method  | : | OECD Test Guideline 405 |

**Titanium dioxide:**

|         |   |                   |
|---------|---|-------------------|
| Species | : | Rabbit            |
| Result  | : | No eye irritation |

**Respiratory or skin sensitization****Skin sensitization**

May cause an allergic skin reaction.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Sitagliptin Phosphate:**

|           |   |                               |
|-----------|---|-------------------------------|
| Test Type | : | Local lymph node assay (LLNA) |
| Species   | : | Mouse                         |
| Method    | : | OECD Test Guideline 429       |
| Result    | : | Not a skin sensitizer.        |

**Simvastatin:**

|            |   |                                                         |
|------------|---|---------------------------------------------------------|
| Assessment | : | Probability or evidence of skin sensitization in humans |
| Result     | : | positive                                                |

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

---

**Starch:**

|                    |                     |
|--------------------|---------------------|
| Test Type          | : Maximization Test |
| Routes of exposure | : Skin contact      |
| Species            | : Guinea pig        |
| Result             | : negative          |

**Ascorbic acid:**

|                    |                            |
|--------------------|----------------------------|
| Test Type          | : Maurer optimisation test |
| Routes of exposure | : Skin contact             |
| Species            | : Guinea pig               |
| Result             | : negative                 |

**Titanium dioxide:**

|                    |                                 |
|--------------------|---------------------------------|
| Test Type          | : Local lymph node assay (LLNA) |
| Routes of exposure | : Skin contact                  |
| Species            | : Mouse                         |
| Result             | : negative                      |

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Sitagliptin Phosphate:**

|                       |                                                                                                                                                                                                                                                                                                                       |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Genotoxicity in vitro | : Test Type: Ames test<br>Result: negative<br><br>Test Type: Chromosome aberration test in vitro<br>Test system: Chinese hamster ovary cells<br>Result: negative<br><br>Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)<br>Test system: rat hepatocytes<br>Result: negative |
| Genotoxicity in vivo  | : Test Type: Micronucleus test<br>Species: Mouse<br>Application Route: Oral<br>Result: negative                                                                                                                                                                                                                       |

**Cellulose:**

|                       |                                                                                                                                                           |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES)<br>Result: negative<br><br>Test Type: In vitro mammalian cell gene mutation test<br>Result: negative |
| Genotoxicity in vivo  | : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)<br>Species: Mouse<br>Application Route: Ingestion                        |

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

---

Result: negative

**Simvastatin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Test Type: Chromosomal aberration  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**Starch:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**Ascorbic acid:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Titanium dioxide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse  
Result: negative

## Sitagliptin / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

---

**Carcinogenicity**

Not classified based on available information.

**Components:****Sitagliptin Phosphate:**

|                   |            |
|-------------------|------------|
| Species           | : Mouse    |
| Application Route | : Oral     |
| Exposure time     | : 2 Years  |
| Result            | : negative |

|                   |                                            |
|-------------------|--------------------------------------------|
| Species           | : Rat                                      |
| Application Route | : oral (drinking water)                    |
| Exposure time     | : 2 Years                                  |
| Result            | : positive                                 |
| Target Organs     | : Liver                                    |
| Remarks           | : Significant toxicity observed in testing |

|                              |                                                                      |
|------------------------------|----------------------------------------------------------------------|
| Carcinogenicity - Assessment | : Weight of evidence does not support classification as a carcinogen |
|------------------------------|----------------------------------------------------------------------|

**Cellulose:**

|                   |             |
|-------------------|-------------|
| Species           | : Rat       |
| Application Route | : Ingestion |
| Exposure time     | : 72 weeks  |
| Result            | : negative  |

**Simvastatin:**

|                   |                                                                 |
|-------------------|-----------------------------------------------------------------|
| Species           | : Mouse                                                         |
| Application Route | : Oral                                                          |
| Exposure time     | : < 92 weeks                                                    |
| Target Organs     | : Harderian gland                                               |
| Tumor Type        | : Liver, Lungs                                                  |
| Remarks           | : The significance of these findings for humans is not certain. |

|                   |                                                                 |
|-------------------|-----------------------------------------------------------------|
| Species           | : Rat                                                           |
| Application Route | : Oral                                                          |
| Exposure time     | : 2 Years                                                       |
| Tumor Type        | : Liver, Thyroid                                                |
| Remarks           | : The significance of these findings for humans is not certain. |

**Ascorbic acid:**

|                   |             |
|-------------------|-------------|
| Species           | : Mouse     |
| Application Route | : Ingestion |
| Exposure time     | : 2 Years   |
| Result            | : negative  |

**Titanium dioxide:**

|                   |                               |
|-------------------|-------------------------------|
| Species           | : Rat                         |
| Application Route | : inhalation (dust/mist/fume) |
| Exposure time     | : 2 Years                     |
| Method            | : OECD Test Guideline 453     |

## Sitagliptin / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

|                              |   |                                                                         |
|------------------------------|---|-------------------------------------------------------------------------|
| Result                       | : | positive                                                                |
| Remarks                      | : | The mechanism or mode of action may not be relevant in humans.          |
| Carcinogenicity - Assessment | : | Limited evidence of carcinogenicity in inhalation studies with animals. |

**Reproductive toxicity**

Not classified based on available information.

**Components:****Sitagliptin Phosphate:**

|                              |   |                                                                                                                                                                                                                                                                                                                                                                                             |
|------------------------------|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effects on fertility         | : | Test Type: Fertility/early embryonic development<br>Species: Rat<br>Application Route: Oral<br>Fertility: NOAEL Parent: 1.000 mg/kg body weight<br>Result: Animal testing did not show any effects on fertility.                                                                                                                                                                            |
| Effects on fetal development | : | Test Type: Embryo-fetal development<br>Species: Rat<br>Application Route: Oral<br>Teratogenicity: LOAEL: 250 mg/kg body weight<br>Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.<br><br>Test Type: Embryo-fetal development<br>Species: Rabbit<br>Teratogenicity: NOAEL: 125 mg/kg body weight<br>Result: No teratogenic effects. |

**Cellulose:**

|                              |   |                                                                                                                           |
|------------------------------|---|---------------------------------------------------------------------------------------------------------------------------|
| Effects on fertility         | : | Test Type: One-generation reproduction toxicity study<br>Species: Rat<br>Application Route: Ingestion<br>Result: negative |
| Effects on fetal development | : | Test Type: Fertility/early embryonic development<br>Species: Rat<br>Application Route: Ingestion<br>Result: negative      |

**Simvastatin:**

|                              |   |                                                                                                                                                                                               |
|------------------------------|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effects on fertility         | : | Test Type: Fertility<br>Species: Rat, male<br>Application Route: Oral<br>Fertility: LOAEL: 25 mg/kg body weight                                                                               |
| Effects on fetal development | : | Test Type: Embryo-fetal development<br>Species: Rat<br>Application Route: Oral<br>Embryo-fetal toxicity.: NOAEL: 25 mg/kg body weight<br>Result: No teratogenic effects., No adverse effects. |

## Sitagliptin / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

---

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-fetal toxicity.: NOAEL: 10 mg/kg body weight  
Result: No teratogenic effects., No adverse effects.

Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Embryo-fetal toxicity.: LOAEL: 60 mg/kg body weight  
Result: Teratogenic potential.  
Remarks: Based on data from similar materials

**Ascorbic acid:**

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

May cause damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.

**Components:****Simvastatin:**

Target Organs : Liver, muscle, optic nerve, Eye  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Sitagliptin Phosphate:**

Species : Mouse  
NOAEL : 500 mg/kg  
LOAEL : 1.000 mg/kg  
Application Route : Oral  
Exposure time : > 2 y  
Target Organs : Kidney

Species : Rat  
NOAEL : 500 mg/kg  
LOAEL : 1.000 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

NOAEL : 10 mg/kg  
LOAEL : 50 mg/kg  
Application Route : Oral  
Exposure time : 53 Weeks  
Target Organs : Central nervous system  
Symptoms : Loss of balance  
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Dog  
NOAEL : 2 mg/kg  
LOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 27 Weeks  
Target Organs : Skeletal muscle, Central nervous system  
Symptoms : Loss of balance  
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Monkey  
NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Remarks : No significant adverse effects were reported

**Cellulose:**

Species : Rat  
NOAEL :  $\geq 9.000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Simvastatin:**

Species : Rat  
NOAEL : 5 mg/kg  
LOAEL : 30 mg/kg  
Application Route : Oral  
Exposure time : 14 - 104 Weeks  
Target Organs : Liver, Testis, Musculo-skeletal system, Eye

Species : Dog  
LOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 14 - 104 Weeks  
Target Organs : Liver, Testis, Eye

Species : Rabbit  
NOAEL : 30 mg/kg  
LOAEL : 50 mg/kg  
Application Route : Oral  
Target Organs : Liver, Kidney

**Starch:**

Species : Rat

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

NOAEL :  $\geq 2.000$  mg/kg  
Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

**Ascorbic acid:**

Species : Rat, male  
NOAEL :  $\geq 8.100$  mg/kg  
Application Route : Ingestion  
Exposure time : 13 Weeks

**Titanium dioxide:**

Species : Rat  
NOAEL : 24.000 mg/kg  
Application Route : Ingestion  
Exposure time : 28 Days

Species : Rat  
NOAEL : 10 mg/m<sup>3</sup>  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 2 y

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Sitagliptin Phosphate:**

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis, Headache  
Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhea

**Simvastatin:**

Skin contact : Remarks: May produce an allergic reaction.  
Ingestion : Target Organs: Liver  
Symptoms: upper respiratory tract infection, Headache, Abdominal pain, constipation, Nausea  
Target Organs: Musculo-skeletal system

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Sitagliptin Phosphate:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

## Sitagliptin / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 60 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 2,2 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 9,2 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 9,8 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211
- Toxicity to microorganisms : EC50: > 150 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209
- NOEC: 150 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition

**Cellulose:**

- Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Simvastatin:**

- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2,91 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 3,5 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 25 mg/l  
Exposure time: 96 h
- NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l  
Exposure time: 96 h
- Toxicity to microorganisms : EC50: > 30 mg/l

## Sitagliptin / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

---

Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 21 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**Ascorbic acid:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 1.020 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to microorganisms : EC50: 140 mg/l  
Exposure time: 16 h  
Method: DIN 38 412 Part 8

**Titanium dioxide:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10.000 mg/l  
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1.000 mg/l  
Exposure time: 3 h  
Method: OECD Test Guideline 209

**Persistence and degradability****Components:****Sitagliptin Phosphate:**

Biodegradability : Result: not rapidly degradable  
Biodegradation: 39,7 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(401 d)  
Method: OECD Test Guideline 111

**Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Simvastatin:**

Biodegradability : Result: rapidly degradable

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

---

Stability in water : Hydrolysis: 50 %(3,2 d)

**Ascorbic acid:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 97 %  
Exposure time: 5 d  
Method: OECD Test Guideline 302

**Bioaccumulative potential****Components:****Sitagliptin Phosphate:**

Partition coefficient: n-octanol/water : log Pow: -0,03

**Simvastatin:**

Partition coefficient: n-octanol/water : log Pow: > 4,07

**Ascorbic acid:**

Partition coefficient: n-octanol/water : log Pow: -1,85

**Mobility in soil****Components:****Sitagliptin Phosphate:**

Distribution among environmental compartments : log Koc: 4,37

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

|                        |                                                                                                                                                               |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Waste from residues    | : Do not dispose of waste into sewer.<br>Dispose of in accordance with local regulations.                                                                     |
| Contaminated packaging | : Empty containers should be taken to an approved waste handling site for recycling or disposal.<br>If not otherwise specified: Dispose of as unused product. |

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

Not applicable

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**SECTION 16. OTHER INFORMATION**

Revision Date : 11.08.2025  
Date format : dd.mm.yyyy

**Further information**

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
AR OEL : Argentina. Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average  
AR OEL / CMP : TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory con-

**Sitagliptin / Simvastatin Formulation**

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024  |
| 8.1     | 11.08.2025     | 24478-00025 | Date of first issue: 21.10.2014 |

---

centration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8